Decellularized omentum as novel biologic scaffold for reconstructive surgery and regenerative medicine

A. Porzionato,1 M.M. Sfriso,1 V. Macchi,1 A. Rambildo,1 G. Lago,2 L. Lancerotto,2 V. Vindigni,2 R. De Caro1

1Section of Human Anatomy, Department of Molecular Medicine, University of Padua; 2Clinic of Plastic Surgery, University of Padua, Italy

Abstract

Homologous tissues, such as adipose tissue, may be an interesting source of acellular scaffolds, maintaining a complex physiological three-dimensional (3D) structure, to be recellularized with autologous cells. The aim of the present work is to evaluate the possibility of obtaining homologous acellular scaffolds from decellularization of the omentum, which is known to have a complex vascular network. Adult rat and human omenta were treated with an adapted decellularization protocol involving mechanical rupture (freeze-thaw cycles), enzymatic digestion (trypsin, lipase, deoxyribonuclease, ribonuclease) and lipid extraction (2-propanol). Histological staining confirmed the effectiveness of decellularization, resulting in cell-free scaffolds with no residual cells in the matrix. The complex 3D networks of collagen (azan-Mallory), elastic fibers (Van Gieson), reticular fibers and glycosaminoglycans (PAS) were maintained, whereas Oil Red and Sudan stains showed the loss of lipids in the decellularized tissue. The vascular structures in the tissue were still visible, with preservation of collagen and elastic wall components and loss of endothelial (anti-CD31 and -CD34 immunohistochemistry) and smooth muscle (anti-alpha smooth muscle actin) cells. Fat-rich and well vascularized omental tissue may be decellularized to obtain complex 3D scaffolds preserving tissue architecture potentially suitable for recellularization. Further analyses are necessary to verify the possibility of recolonization of the scaffold by adipose-derived stem cells in vitro and then in vivo after re-implantation, as already known for homologous implants in regenerative processes.

Introduction

In reconstructive surgery and regenerative medicine, tissue implants are useful in treating post-operative, congenital or post-traumatic loss of subcutaneous fat layers, which may result in scar tissue formation, deformity, and loss of function. Autologous, allogenic or alloplastic materials may be used for soft tissue augmentation.1 Many kinds of scaffolds have been developed, both naturally derived, like collagen,2 fibrin,1 derivatives of hyaluronan1 and silk protein,3 and synthetic, like polyactic-co-glycolic acid,4 polyglycolic acid5 and polyethylene glycol diacrylate.6 These matrices are usually seeded with human- or animal-derived primary cells or cell lines to evaluate the proliferative and differentiative responses in vitro and in vivo.7 Scaffolds must satisfy specific conditions, such as mechanical or material properties which make them suitable for incorporation in the host site: for example, they should be capable of mimicking native tissues into which they are placed in and minimizing any inflammation events or scar tissue formation.8,9 Synthetic implants are more frequently associated with immune rejection, allergic reactions, or implant migration and resorption, with consequent failure to integrate into the host tissues. For these reasons, tissue-engineered adverse substitutes, promoting regeneration rather than repair, have been developed, although it is not simple to maintain physiologic irritation after tissue re-implant.10 The greater omentum has been employed in various surgical procedures, because of its rich vascular supply with high capacity for absorption, pronounced angiogenic activity supporting hypoxic/ischemic tissues, innate immune function, ability to adhere to local structures, and high concentration of growth factors and factors promoting hemostasis.11-15 In particular, in hypoxic and traumatic conditions, omental adipocytes have been observed to increase the expression of angiogenic factors, mainly vascular endothelial growth factor (VEGF).15-17 The aim of the present work is to evaluate the effects of a decellularization protocol involving mechanical, enzymatic and lipid extractive mechanisms on the tissue architecture of rat and human omentum, to develop a novel scaffold suitable for autologous re-cellularization and implant in reconstructive surgery.

Materials and Methods

Male and female Sprague-Dawley rats were used according to the Italian Public Health Office regulations and European Communities Council Directive of 24 November 1986 (86/609/EEC). After an abdominal cut the greater omentum was resected and washed in sterile fresh cation-free phosphate buffered saline (PBS, Sigma-Aldrich, Milan, Italy) supplemented with 20 mg/mL bovine serum albumin (BSA, Sigma-Aldrich) within 2 h of extraction. Samples of human omentum were collected from autopsies of adult subjects. Samples were delivered to the laboratory on ice for processing within 2 h in sterile fresh PBS supplemented with 20 mg/mL BSA.

Decellularization of omentum

Briefly, adult rat and human omenta were treated with the following 5-day decellularization protocol involving mechanical rupture, polar solvent extraction, and enzymatic digestion. The protocol was mainly derived from previous studies on decellularization of placenta20 and adipose tissue21 and differs from methods proposed in a recent patent for the use of decellularized omentum matrix.22 Optimal incubation times in the different decellularization solutions were identified through intermediate morphologic analyses and DNA quantifications. The differences in incubation times between rats and humans mainly rely on tissue size, although the human omentum also showed higher tissue density and fat content than rat omentum. The following protocol refers to decellularization of samples of human omentum of 2×2 cm. Incubation times in the case of decellularization of rat samples (about 1×1 cm in size) were about 50% shorter. Within 2 h of sampling, all pieces first underwent three freeze-thaw cycles (from -80°C to 37°C) in Freezing Buffer solution, containing 10 nM Tris base (Sigma-Aldrich) and 5 mM ethylenediaminetetraacetic acid (EDTA, Sigma Aldrich) at pH 8.0. The tissues were then transferred to Enzymatic Solution #1, composed of 0.25% trypsin and 0.1% EDTA (Invitrogen, Milan, Italy) and incubated for 16 h at 37°C, with shaking to separate cells. The following
day, the tissues were treated with a polar-solvent extraction solution, composed of 2-
propanol 99.9% (Sigma-Aldrich) for 48 h with shaking, to remove any lipid components. 
Subsequently, samples were rinsed 3 times for 30 min in Rinsing Buffer Solution, made up of 8
mM NaCl, 200 mM KCl, 1 mM NaHPO₄, and 200
mM KH₂PO₄ (all reagents from Sigma-Aldrich) at pH 8.0, to remove any 2-propanol residues,
and underwent then further Enzymatic Solution #1 digestion for 6 h at 37°C with shaking.
Following 3 more wash cycles in Rinsing Buffer Solution, the tissues were incubated with
Enzymatic Solution #2, containing 55 mM NaHPO₄, 17 mM KH₂PO₄, 4.9 mM MgSO₄·7H₂O,
15,000 U deoxyribonuclease I type II (from bovine pancreas), 12.5 μg ribonuclease type
III (from bovine pancreas), 2000 U lipase type VI-S (from porcine pancreas) (all reagents from
Sigma-Aldrich) for 16 h. At the end of digestion #2, treated tissues were rinsed 3 times in
Rinsing Buffer Solution and subjected to a final polar solvent extraction for 6 h. At the end of
processing, the decellularized matrix was rinsed three times in Rinsing Buffer Solution, three
times in 70% ethanol, and then stored in sterile PBS supplemented with 1% antibiotic-
antimycotic solution (ABAM, A5955, Sigma-Aldrich) at 4°C.
All decellularization solutions were supple-
mented with 1% ABAM. Moreover, all decellu-
larization solutions with the exception of
Enzymatic Solution #1 were also supplemented
with 1% phenylmethanesulphonylfluoride
(PMSF, Sigma-Aldrich).

**Histological and immunohistochemical analysis**

Samples of human and rat omentum before
and after decellularization were fixed in 10%
neutral buffered formalin for 24 h, embedded in
paraffin and cut into 3-μm thick sections. In
particular, representative samples were taken from various regions of the decellularized
scaffold, including the most central regions and
the external surfaces. The following histo-
chemical stainings were performed: Hematoxylin and Eosin (H&E), azan-Mallory,
Van Gieson, PAS. Samples were also frozen on dry ice and stored at -80°C for
analysis.

**Results**

From a macroscopic point of view, the decel-
larization protocol, mainly during 2-iso-
propanol incubation, caused the loss of the
lipid components of the samples, which passed
toward the upper phase of the solution in the
form of oil drops. As a result of lipid loss, omental samples changed color, from yellow to
whitish. The decellularized samples preserved
their volume, and did not show rupture of the
tissue, although a slight reduction in consist-
ency was observed.

Both in rat and human samples, histological
stains showed loss of the cellular omental com-
ponents and preservation of the 3D archite-
ecture of connective fibers (Figures 1 and 2).
In particular, azan-Mallory, and van Gieson
showed the persistence of collagen and elastic
fibers, respectively, around the spaces previ-
ously occupied by adipocytes. Azan-Mallory
identified many blue collagen fibers, which
appeared to be packed densely and arranged in
ordered bundles in the bulk of the material.
Van Gieson showed elastic fibers organized in
a quite complex 3D network surrounding
adipocytes. PAS staining also showed the pre-
sistence of reticular fibers and glycosaminogly-
cans, which colored violet by this staining. Oil Red and Sudan stains also confirmed the
loss of adipocytes and lipids from omental tis-
sue after decellularization (Figure 3).

Analysis of the vascular components also
showed that decellularization preserved vessel
profiles, the lumens remaining visible with
preservation of collagen and elastic fibers in
the vessel walls in sections stained with azan-
Mallory and van Gieson (Figures 4 and 5).
Conversely, anti-CD31 and -CD34 immunohis-
tochemical analyses showed the complete loss
of immunostained endothelial cells (Figure 6).
Anti-Smooth Muscle Actin immunohistochem-
istry also showed the absence of smooth mus-
cle cells in vessel profiles exposed to decellu-
larization (Figure 7).

**Discussion**

Omentum has frequently been used, as a
pedunculated or free flap, in several kinds of sur-
gery, thanks to its angiogenic and regenerative
properties. For instance, it has been used to
cover colonic/colorectal, esophageal/esopha-
gogastric and tracheobronchial anastomoses,
to manage perforated gastric/duodenal ulcers and to reduce bleeding in hepatectomy or pan-
creatosplenectomy. In pelvic irradiation, omental flap transpositions have also
been used to exclude and protect the small
bowel and bladder from the radiation field.
Laparotomically or laparoscopically harvested omental flaps have been used for reconstructive surgery of superficial extra-abdominal structures. For instance, they have been used to treat large scalp defects, sternal wound infections after sternotomy for coronary artery bypass grafting, scrotal reconstruction, soft tissue augmentation of breasts and facial contour defects. In rats, fragmented omental tissues, with or without co-transplantation with preadipocytes, have been proved potentially useful for soft tissue augmentation. In pigs, omentum has also been wrapped around a scaffold made up of small intestinal submucosa matrix seeded with autologous urothelium and smooth muscle cell primary cultures, in order to develop engineered bladders and neoureters. In these latter cases, omentum provided autologous support for the growth and differentiation of the seeded cells, functioning as an in vivo bioreactor. A patent has also been published about methods for extracting fat from omentum and for applying decellularized omentum for tissue engineering. In this study, we demonstrated the possibility of decellularizing human omentum in order to obtain a biologic scaffold, with preservation of the three-dimensional structure of the extracellular matrix.

Several biological scaffolds derived from decellularization of human or animal materials have been approved for use in human patients. As regards allogenic scaffolds, it is worth mentioning products derived from decellularization of human dermis (AlloDerm®, LifeCell, Corp; Axis™ dermis, Mentor, etc.), fascia lata (AlloPatch®, Musculoskeletal Transplant Foundation; FasLata®, Bard) or pericardium (IOPatch™, IOP Inc.) Decellularized placental matrix has also been proposed as a tissue-engineered adipose substitute. In particular, the complex vascular network of the human placenta has been suggested to be useful for revascularization. Xenogenic biological scaffolds derived from porcine mesothelium (Meso BioMatrix™, Kensey Nash Corp.) are also commercially available. Conversely, apart from the above patent, biological scaffolds obtained by decellularization of human or animal omentum have not yet been considered in the scientific literature and are not commercially available. In particular, allogenic omentum could be obtained from both living and deceased donors. It could be re-cellularized in vitro through seeding of autologous adipose-derived stem cells and then implanted for soft tissue reconstruction.

Many decellularization protocols have been developed to obtain biologic scaffolds composed of extracellular matrix. Decellularization should ensure the removal of all residual cellular material and preserve the native architecture, ultrastructure and composition of the extracellular matrix. Residual cellular material may induce adverse host responses after implantation. Conversely, a preserved extracellular matrix may induce cell mitogenesis, chemotaxis and differentiation, favoring a...
constructive host tissue remodeling response. The integrity of the material should avoid any phenomena of degradation after tissue reconstruction and must promote tissue regeneration. Decellularized biological scaffolds have the advantage of possessing an extracellular matrix rich in the cell signaling components essential for cell adhesion, migration, proliferation and differentiation.

Decellularization protocols may involve physical, chemical and/or biologic methods. The main physical methods are direct pressure, agitation, sonication, or snap freezing. Chemical agents include acids and bases, hypotonic and hypertonic solutions, detergents and alcohols. Enzymes usually used in decellularization are nucleases, collagenase, trypsin, lipase and others. Non-enzymatic biologic agents are EDTA and EGTA. The patent by Yang et al. involved a first phase of fat removal involving dehydration solvents (methanol, ethanol, isopropanol or propanol) and extraction solvents, both polar (acetone, dioxane or acetonitrile) and non-polar (hexane, xylene, benzene, toluene or ethyl acetate). After rehydration, decellularization phases involved non-ionic detergents, such as TRITON X-100.
metal salts (magnesium chloride, phosphate, acetate or citrate), and an enzyme solution with endonuclease. In the present work, we applied a different decellularization protocol involving multiple methods, i.e., freeze-thaw cycles, agitation, EDTA, trypsin, deoxyribonuclease, ribonuclease, lipase, 2-propanol and ethanol. The use of various methods increases the effectiveness of decellularization by means of different mechanisms. For instance, freezing is useful for disrupting cellular membranes and causing cell lysis, but must be integrated by methods to remove the products of cell lysis. In this sense, EDTA and trypsin are usually used together (in our decellularization protocol, enzymatic solution #1) to remove cellular materials. EDTA disrupts cell adhesion to the extracellular matrix by chelating divalent cations (Ca²⁺ and Mg²⁺) which intervene in cell attachment to collagen and fibronectin. Trypsin cleaves the peptide bonds on the carbon side of arginine and lysine when the next residue is not proline. Obviously, in decellularization of omentum, the main components to be removed are lipids. In our protocol, lipase was the main agent used for delipidation. However, it has been stressed in the literature that lipase, if used alone, is usually not sufficient to remove all lipids and that the use of alcohols is also necessary. The decellularization protocol used in this study showed satisfactory lipid removal, as demonstrated in sections stained with Sudan and Oil Red.

Apart from the above agents used for decellularization, it is worth noting the role played by protease inhibitors and antibiotics in ensuring optimal decellularization. Due to cell lysis, many proteases are released and may damage the native ultrastructure of the extracellular matrix, so that protease inhibitors, such as PMSF used in the present protocol, are usually added. Antibiotics and antimycotics were also used to minimize microbial contamination. However, it has been stressed in the literature that antibiotics/antimycotics remaining in the scaffold after decellularization may increase the complexity of regulatory approval, the biological scaffold being considered a drug rather than a medical device.

A further step of the present work will be recellularization of the scaffold with autologous stem cells before implant. In the patent by Yang et al., decellularized omentum was proposed to be co-cultured with human kidney derived cells, urothelial cells, or endothelial cells in a tubular omentum matrix. However, adipose tissue is also a rich source of stem cells, the so-called adipose-derived stem cells, which have the capacity to differentiate along the adipogenic, chondrogenic, myogenic, osteogenic, neurogenic, and endothelial, smooth muscle lineages. In our opinion, this kind of cells could be the most suitable ones for recellularization process. Autologous adipose-derived stem cells may easily be derived from liposuctioned fat, in which their frequency is much higher than in bone marrow. Structural studies have also stressed that some adipose tissue depots, such as the trochanteric fat pad, are particularly suited for regenerative procedures due to higher dissociability of the adipose elements and richness in stem cells. After a first in vitro recellularization phase, further cell invasion will derive in vivo after implantation, although these aspects must be addressed in future works. Omentum is frequently used in surgery, due to its elevated vascularization. The decellularization protocol used in the present work allowed vessel profiles to be preserved after removal of endothelial and smooth muscle cells, suggesting the possibility of re-cellularizing the omental vascular network with autologous adipose-derived stem cells or also with blood-derived endothelial progenitor cells. The complex microvasculature of omentum may increase the potential of this tissue in reconstructive surgery, also with respect to autologous transplantation of other kinds of adipose tissue. Adipocytes in omentum are characterized by their high production of growth and angiogenic factors, which may also be preserved (at least partly) in decellularized scaffolds, favoring engraftment, proliferation and differentiation of stem cells. After decellularization, the same extracellular matrix may preserve components essential for cell adhesion, migration, proliferation and differentiation.

In conclusion, in this study we present a decellularization protocol which proved effective in removing cell material and maintaining

**Figure 7.** Anti-Smooth Muscle Actin immunohistochemistry of rat (A-B) and human (C-D) omentum, before (A, C) and after (B, D) decellularization protocol, showing loss of immunostained muscle cells in decellularized samples. Scale bars: A-D, 37.5 μm.

**Figure 8.** DAPI staining of rat (A-B) and human (C-D) omentum, before (A, C) and after (B, D) decellularization protocol, showing loss of nuclear material in decellularized samples. Scale bars: A-D, 75 μm.
the extracellular matrix architecture of omentum, stressing the potential of this tissue for developing a new alloegenic biological scaffold to be recellularized with autologous stem cells. Such a scaffold may be a viable alternative in various fields of reconstructive surgery and regenerative medicine.

References

1. Flynn LE, Prestwich GD, Semple JL, Woodhouse KA. Proliferation and differentiation of adipose-derived stem cells on naturally derived scaffolds. Biomaterials 2008;29:1862-71.
2. Gentleman E, Nauman EA, Livesay GA, Dee KC. Collagen composite biomaterials resist contraction while allowing development of adipocytic soft tissue in vitro. Tissue Eng 2006;12:1639-49.
3. Cho SW, Kim SS, Rhee JW, Cho HM, Choi CY, Kim BS. Engineering of volumetable adipose tissues. Biomaterials 2005;26:3577-85.
4. Hemmrich K, von Heimburg D, Rendchen M, Becker C, Hacker M. Generation of adipose-tissue. Tissue Eng Part A 2009;15:2227-36.
5. Patrick CW. Breast tissue engineering. Annu Rev Biomed Eng 2004;6:109-30.
6. Kang JH, Gimble JM, Kaplan DL. In vitro 3-D long-term culture of 3T3-L1 adipocytes. Exp Cell Res 2004;300:54-64.
7. Neubauer M, Hacker M, Bauer-Kreisel P, Weiser B, Fischbach C, Schulz MB. Adipose tissue engineering based on mesenchymal stem cells and basic fibroblast growth factor in vitro. Tissue Eng 2005;11:1840-51.
8. Fischbach C, Spruss T, Weiser B, Neubauer M, Becker C, Hacker M. Generation of mature fat pads in vitro and in vivo utilizing 3-D long-term culture of 3T3-L1 preadipocytes. Exp Cell Res 2004;300:54-64.
9. Alhadlaq A, Tang M, Mao JJ. Engineered adipose tissue from human mesenchymal stem cells maintains predefined shape and dimension: implications in soft tissue augmentation and reconstruction. Tissue Eng 2005;11:536-66.
10. Flynn LE. The use of decellularized adipose tissue to provide an inductive microenvironment for the adipogenic differentiation of human adipose-derived stem cells. Biomaterials 2010;31:4715-24.
11. Cartier R, Brunette I, Hashimoto K, Bourne WM, Schaff HV. Angiogenic factor: a possible mechanism for neovascularization produced by omental pedicles. J Thorac Cardiovasc Surg 1990;99:264-8.
49. Vorotnikova E, McIntosh D, Dewilde A, Brown BN, Valentin JE, Stewart-Akers AM, Gilbert TW, Sellaro TL, Badylak SF. Adipose tissue engineering with cells in engineered extracellular matrix gels. Tissue Eng Part A 2010;16:1075-82.

50. Sellaro TL, Ranade A, Faulk DM, McCabe GP, Dorko K, Badylak SF, et al. Maintenance of human hepatocyte function in vitro by liver-derived extracellular matrix gels. Tissue Eng Part A 2010;16:1075-82.

51. Yow-K-H, Ingram J, Korossis SA, Ingham E, Homer-Vanniasinkam S. Tissue engineering of vascular conduits. Br J Surg 2006;93:652-61.

52. Schenke-Layland K, Vasilevski O, Opitz F, König K, Riemann I, Halbhuber KJ, et al. Impact of decellularization of xenogeneic tissue on extracellular matrix integrity for tissue engineering of heart valves. J Struct Biol 2003;143:201-8.

53. Grauss RW, Hazekamp MG, Oppenhuizen F, van Munsteren CJ, Gittenberger-de Groot AC, DeRuiter MC. Histological evaluation of decellularised porcine aortic valves: matrix changes due to different decellularisation methods. Eur J Cardiothorac Surg 2005;27:3566-71.

54. Brown BN, Freums MA, Han L, Rubis JP, Reing JE, Jeffries EM, et al. Comparison of three methods for the derivation of a biologic scaffold composed of adipose tissue extracellular matrix. Tissue Eng Part C Methods 2011;17:411-21.

55. Gronthos S, Franklin DM, Leddy HA, Robey PG, Storms RW, Gimble JM. Surface protein characterization of human adipose tissue-derived stromal cells. J Cell Physiol 2001;189:54-63.

56. Nathan S, Das De S, Thambyah A, Fen C, Goh J, Lee EH. Cell-based therapy in the repair of osteochondral defects: a novel use for adipose tissue. Tissue Eng 2003;9:733-44.

57. Guijak F, Lott KE, Awad HA, Cao Q, Hicok KC, Fermbor B, et al. Clonal analysis of the differentiation potential of human adipose-derived adult stem cells. J Cell Physiol 2006;206:229-37.

58. Peterson B, Zhang J, Iglesias R, Kabo M, Hedrick M, Benhaim P, et al. Healing of critically sized femoral defects, using genetically modified mesenchymal stem cells from human adipose tissue. Tissue Eng 2005;11:120-9.

59. Zuck PA, Zhu M, Ashjian P, De Ugarte DA, Huang JL, Mizuno H, et al. Human adipose tissue is a source of multipotent stem cells. J Struct Biol 2002;139:95.

60. Planat- Benard V, Silvestre JS, Cousin B, André M, Nibbelink M, Tamarat R, et al. Plasticity of human adipose lineage cells toward endothelial cells: physiological and therapeutic perspectives. Circulation 2004;109:656-63.

61. Miravalle A, Heeschen C, Sengenès C, Curat CA, Busse R, Bouloumé A. Improvement of postnatal neovascularization by human adipose tissue-derived stem cells. Circulation 2004;110:349-55.

62. Cao Y, Sun Z, Liao L, Meng Y, Han Q, Zhao RC. Human adipose tissue-derived stem cells differentiate into endothelial cells in vitro and improve postnatal neovascularization in vivo. Biochem Biophys Res Commun 2005;323:370-9.

63. DiMuzio P, Tulenko T. Tissue engineering applications to vascular bypass graft development: the use of adipose-derived stem cells. J Vasc Surg 2007;45:A99-103.

64. Rodríguez LV, Alfonso Z, Zhang R, Leung J, Wu B, Ignarro LJ. Clonogenic multipotent stem cells in human adipose tissue differentiate into functional smooth muscle cells. Proc Natl Acad Sci USA 2006;103:12167-72.

65. De Ugarte DA, Morizono K, Elbarbary A, Alfonso Z, Zuck PA, Zhu M, et al. Comparison of multi-lineage cells from human adipose tissue and bone marrow. Cells Tissues Organs 2003;174:101-9.

66. Sbrabiati A, Accorsi D, Benati D, Marchetti L, Orsini G, Rigotti G, et al. Subcutaneous adipose tissue classification. Eur J Histoch 2010;54:e48.

67. Panettiere P, Accorsi D, Marchetti L, Minicuzzi AM, Orsini G, Bernardi F, et al. The trochanteric fat pad. Eur J Histoch 2011;35:e16.